Neoplasms, Glandular and Epithelial
"Neoplasms, Glandular and Epithelial" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
| Descriptor ID |
D009375
|
| MeSH Number(s) |
C04.557.470
|
| Concept/Terms |
Neoplasms, Glandular and Epithelial- Neoplasms, Glandular and Epithelial
- Neoplasms, Glandular Epithelial
- Epithelial Neoplasm, Glandular
- Epithelial Neoplasms, Glandular
- Glandular Epithelial Neoplasm
- Glandular Epithelial Neoplasms
- Neoplasm, Glandular Epithelial
- Glandular and Epithelial Neoplasms
Glandular Neoplasms- Glandular Neoplasms
- Glandular Neoplasm
- Neoplasm, Glandular
- Neoplasms, Glandular
|
Below are MeSH descriptors whose meaning is more general than "Neoplasms, Glandular and Epithelial".
Below are MeSH descriptors whose meaning is more specific than "Neoplasms, Glandular and Epithelial".
- Neoplasms, Glandular and Epithelial
- Adenoma
- Carcinoma
- Neoplasms, Adnexal and Skin Appendage
- Neoplasms, Basal Cell
- Neoplasms, Cystic, Mucinous, and Serous
- Neoplasms, Ductal, Lobular, and Medullary
- Neoplasms, Fibroepithelial
- Neoplasms, Mesothelial
- Neoplasms, Neuroepithelial
- Neoplasms, Squamous Cell
This graph shows the total number of publications written about "Neoplasms, Glandular and Epithelial" by people in this website by year, and whether "Neoplasms, Glandular and Epithelial" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 1 | 3 |
| 2011 | 5 | 4 | 9 |
| 2012 | 3 | 0 | 3 |
| 2013 | 5 | 0 | 5 |
| 2014 | 6 | 0 | 6 |
| 2015 | 1 | 0 | 1 |
| 2016 | 6 | 0 | 6 |
| 2017 | 12 | 0 | 12 |
| 2018 | 4 | 1 | 5 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasms, Glandular and Epithelial" by people in Profiles.
-
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019 11 14; 381(20):1929-1939.
-
Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2018 11; 151(2):257-263.
-
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol. 2018 08; 150(2):247-252.
-
Correlation of clinical data with fallopian tube specimen immune cells and tissue culture capacity. Tissue Cell. 2018 Jun; 52:57-64.
-
Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018 06; 149(3):525-530.
-
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. Gynecol Oncol. 2018 04; 149(1):214-220.
-
Cytologic findings of spindle epithelial tumor with thymus-like elements. Laryngoscope. 2018 02; 128(2):E78-E82.
-
Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol. 2018 02; 148(2):275-280.
-
Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol. 2018 01; 148(1):49-55.
-
Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. Gynecol Oncol. 2017 12; 147(3):509-513.